AzTrials
AzTrials

COVID-19 PandemicCOVID-19NCT05264948

Seasonal Factors and COVID 19

An observational study of COVID-19 Pandemic, run by Izmir Katip Celebi University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Corona Virus - 19 Disease (COVID-19), caused by Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2), first appeared in Wuhan city of Hubei province of China and spread rapidly, causing a pandemic. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
COVID-19 Pandemic
What is being tested?
Polymerase chain reaction
How many people
24,225 participants
Where
1 siteTurkey (Türkiye)
Study dates
31 Jan 2021to 2 Mar 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with positive PCR test according to laboratory, imaging and PCR test results from adult patients who applied with Covid-19 symptoms or contact history, and patients diagnosed with COVID-19 as a result of imaging and clinical findings were included in the study. Patients under the age of 18 were excluded from these patients.

Who may be able to join

  • Patients with positive PCR test according to laboratory, imaging and PCR test results from adult patients who applied with Covid-19 symptoms or contact history, and patients diagnosed with COVID-19 as a result of imaging and clinical findings were included in the study.

Who cannot join

  • Patients under the age of 18 were excluded from these patients.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • IKCU, Atatürk Eğitim ve Araştırma Hastanesi, Acil Tıp

    Izmir, 35360

Other trials in Turkey (Türkiye)

About this study

Official title: The Effect of Seasonal Factors on the Virulence and Mortality of COVID 19

Corona Virus - 19 Disease (COVID-19), caused by Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2), first appeared in Wuhan city of Hubei province of China and spread rapidly, causing a pandemic. In the period from the first emergence of the disease to the present, 336,790,193 people have been infected and 5,560,718 people have died. Considering the severity of the disease, some quarantine measures should be applied, as in many infectious diseases, among the first measures taken worldwide to prevent the spread of the virus.It has been suggested in a limited number of studies conducted in the last two years that climatic conditions may be among the main factors affecting the spread of SARS-CoV-2. However, there is no consensus on the effects of factors such as temperature, humidity, and wind on the spread of the disease, and there are conflicting results. The aim of this study is to determine the relationship between the rate of spread of COVID-19, the rate of intensive care hospitalization and fatality, and weather conditions.

Read the detailed description

From the first appearance of COVID-19 to the present, 336,790,193 people have been infected and 5,560,718 people have died (Web Page: https://covid19.who.int/ accessed on 21 January 2022). Considering the severity of the disease, some quarantine measures should be applied, as in many infectious diseases, among the first measures taken worldwide to prevent the spread of the virus. However, these practices may cause the society to be negatively affected economically, socially and psychologically over time (1). Predicting the conditions that increase the spread of the disease, optimizing quarantine practices, preparing health institutions for epidemic disease conditions and minimizing the negative effects of practices on society are very important in such pandemic epidemics that have the potential to affect the whole world for years.

In the last two decades, it has been reported that the survival time of the virus in the air, its spreading rate and virulence are affected by weather conditions such as temperature, humidity, and wind speed in epidemics caused by viruses that are transmitted by droplets and cause respiratory diseases (2,3). Similarly, a limited number of studies conducted in the last two years have suggested that climatic conditions may be among the main factors affecting the spread of SARS-CoV-2 (1.4-6). In addition, almost all of these studies were carried out on the basis of the number of patients presented by the health authorities of the countries, and they are not field studies. This situation, on the other hand, has the potential to ignore patients who have only Polymerase Chain Reaction (PCR) positivity as the basis for patient identification, and therefore patients with clinical and imaging COVID-19 and test negativity. While investigating the relationship between the rate of spread and virulence of COVID-19 and seasonal climatic conditions, conducting the study in a region where all the factors that have the potential to affect the spread of the virus are as similar as possible, over a wide period of time, including seasonal changes, may provide more information. The aim of this study is to determine the relationship between the rate of spread of COVID-19, the rate of intensive care hospitalization and fatality, and weather conditions.

This retrospective observational multicenter study was conducted by examining the 284-day data of Covid-19 outpatient clinics of two large University hospitals located in the south and north of the city of Izmir in Turkey. The province of İzmir, where the research was carried out, is located between 38-39 north latitudes and 26-28 east meridians in terms of geographical location. It is Turkey's 3rd largest city and its total population in 2020 is approximately 4.4 million people. The centers where the study was conducted are the university hospitals in the north and south of the city, which have been serving as pandemic centers since the beginning of the pandemic and where the city's highest number of patient admissions. Before starting the study, approval was obtained from the hospital local ethics committee with the number GOKAE-2020-190 and from the Ministry of Health with the number 2020-05-04T09_17_13.

The data were obtained by examining the patient records who applied to the COVID-19 outpatient clinics of both central hospitals where the study was conducted between March 2020 and January 2021. The data were analyzed day by day, covering 284 days. During the study period, the number, gender, age and clinical outcome of all patients with positive PCR test among the patients who applied to the Covid outpatient clinics of both hospitals (decision of outpatient follow-up, decision of hospitalization, decision of admission to intensive care unit and ex) were recorded. . Patients who were diagnosed with COVID-19 based on clinical and imaging studies and were therefore recommended isolation or hospitalization were enrolled among the patients who had negative PCR tests. While patients with negative PCR were diagnosed with Covid-19 in their applications to the Covid-19 outpatient clinics of both hospitals, the North American Society of Radiology Covid-19 CT imaging expert consensus report is taken as a basis for radiological images. According to this report, those with Lung CT Type 1 or Type 2 are considered Covid-19, while those with Type 3 or who are clinically compatible with Covid-19 in patients with no infiltration on imaging or who were not sent for imaging, accompanied by normal or low white blood cell count and low neutrophil count, have high Patients are diagnosed with Covid-19 using platelet count parameters. The hospital records of these patients were reviewed, and patients whose diagnosis changed according to repeated PCR test, swab test results for other viral agents, repetitive imaging, and laboratory results were excluded from the study. Clinical outcome was followed up 1 month after the first admission of the patients and until discharge or death in hospitalized patients. The application date of the patients who had recurrent applications during the same disease process was taken as the first application date, and the records of the patients whose clinical decision was later changed to hospitalization and intensive care unit were reduced to a single record and the final clinical outcome was taken as the basis. In this way, the number of patients who received outpatient treatment, hospitalized, intensive care and ex-patient treatment due to Covid-19 were determined and recorded. The rate of hospitalization of the patients in the intensive care unit was calculated with the formula of the number of patients admitted to the daily intensive care unit / Number of patients diagnosed with covid daily, and the fatality rate was calculated with the formula: Number of patients who died per day / Number of patients diagnosed with daily covid, and was recorded.

Weather data with official application from the General Directorate of Meteorology, daily minimum temperature (°C), maximum temperature (°C), temperature average (°C), wind speed (m/s) and direction, humidity (%) within the working period. was obtained as the amount of precipitation (kg/m2).

Descriptive statistics; frequency, percentage, mean, standard deviation, median, minimum and maximum values will be obtained. Number and percentage for categorical variables, mean, standard deviation, minimum, maximum values and interquartile range (IQR) for numerical variables will be calculated. Histogram curves, kurtosis-skewness values and the Shapiro-Wilks test will be used to test whether the continuous variables are normally distributed. The seasonal parameters, temperature, humidity, wind and precipitation, will be correlated with the number of patients per day. By obtaining the same parameters and the graph showing the distribution with the number of patients, the temperature, humidity, wind and precipitation levels with the increase in the number of patients will be determined.

Keywords
COVID-19, SARS-CoV-2, Seasonal Variation
Medical subject headings
COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The rate of spread of SARS-CoV-2

    Number of Covid-19 cases per day

    Measured: 284 day

Secondary outcomes (2)
  1. Intensive care hospitalization rate

    Number of Intensive care hospitalized Covid-19 patients

    Measured: 284 day

  2. Covid-19 fatality rate

    Number of died patients due Covid-19 daily

    Measured: 284 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Mar 2022
  2. Study start31 Jan 2021
  3. Primary completion1 Jan 2022
  4. Study completion2 Mar 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case crossover
Time perspective
Retrospective
Enrolment
24,225 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05264948
Sponsor's protocol ID
GOKAE-2020-190
Acronym
COVID-19
Status last verified
Mar 2022
First submitted
1 Mar 2022
Last updated
3 Mar 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All data other than the personal information of the participants can be shared.

Publications

  • Scafetta N. Distribution of the SARS-CoV-2 Pandemic and Its Monthly Forecast Based on Seasonal Climate Patterns. Int J Environ Res Public Health. 2020 May 17;17(10):3493. doi: 10.3390/ijerph17103493.

    PubMed 32429517
  • Shaman J, Kohn M. Absolute humidity modulates influenza survival, transmission, and seasonality. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3243-8. doi: 10.1073/pnas.0806852106. Epub 2009 Feb 9.

    PubMed 19204283
  • Lipsitch M, Viboud C. Influenza seasonality: lifting the fog. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3645-6. doi: 10.1073/pnas.0900933106. No abstract available.

    PubMed 19276125
  • Wu T, Kang S, Peng W, Zuo C, Zhu Y, Pan L, Fu K, You Y, Yang X, Luo X, Jiang L, Deng M. Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19). Front Med (Lausanne). 2021 Jul 6;8:702066. doi: 10.3389/fmed.2021.702066. eCollection 2021.

    PubMed 34295915
  • Tosepu R, Gunawan J, Effendy DS, Ahmad OAI, Lestari H, Bahar H, Asfian P. Correlation between weather and Covid-19 pandemic in Jakarta, Indonesia. Sci Total Environ. 2020 Jul 10;725:138436. doi: 10.1016/j.scitotenv.2020.138436. Epub 2020 Apr 4.

    PubMed 32298883
  • Ma Y, Zhao Y, Liu J, He X, Wang B, Fu S, Yan J, Niu J, Zhou J, Luo B. Effects of temperature variation and humidity on the death of COVID-19 in Wuhan, China. Sci Total Environ. 2020 Jul 1;724:138226. doi: 10.1016/j.scitotenv.2020.138226. Epub 2020 Mar 26.

    PubMed 32408453

Questions about this trial

What is this clinical trial studying?

An observational study of COVID-19 Pandemic, run by Izmir Katip Celebi University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The rate of spread of SARS-CoV-2 (time frame: 284 day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05264948, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in